RE: To DE or Not to DE25 Oct 2022 19:10
So your rationale is that if we get great safety data, proof of mechanism, biopsies and other data that’s all positive that you’d value Avacta at around 350-70m or so Mcap, based on what could amount to an early proof of a platform over a dozen or more pro drugs, each with a market worth billions? Not factoring in the likelihood it would also lead to a potential licensing deal for ava3996. If the above is all shown within the next AVA6000 RNS then I’d be amazed if we don’t land north of £2:50 and fair value based on current funding to circa end 2024 id say we should be closer to the £3-3:50 mark. So I’m going to say with a fair wind, £2 plus conservative estimate for end of year.